Vazalore 325 mg
Our lead product, Vazalore 325 mg, is NDA-approved by the FDA for OTC distribution and is the first-ever FDA-approved liquid-filled aspirin capsule. All the clinical trials necessary for product launch have been completed.
Vazalore: Unlocking Aspirin’s Full Potential
Comparative Efficacy of
Aspirin Formulations
PL2200 = ValaloreTM
Vazalore achieves therapeutic efficacy 4 times faster than EC Aspirin
Bhatt DL, et al. Enteric Coating and Aspirin Non-Responsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol 2017 Feb 14;69(6):603-612
PK/PD Comparison of ASA, ECASA & Vazalore:
Implications for Aspirin Efficacy
PL2200 = ValaloreTM
Vazalore has up to 5X greater absorption than enteric coated aspirin
Bhatt DL, et al. Enteric Coating and Aspirin Non-Responsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol 2017 Feb 14;69(6):603-612
PK/PD Comparison of ASA, ECASA & Vazalore:
Implications for Aspirin Efficacy
PL2200 = ValaloreTM
Vazalore delivers 2X better platelet response than enteric coated aspirin
Bhatt DL, et al. Enteric Coating and Aspirin Non-Responsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol 2017 Feb 14;69(6):603-612
Endoscopic Assessment of Aspirin Formulations:
Implications for Gastric Ulcer Risk
PL2200 = ValaloreTM
Vazalore vs. Aspirin:
47% lower risk of erosions or ulcers (NNT 5)
71% lower risk of ulcers (NNT 8)
Cryer B, et al. Low-Dose Aspirin-Induced Ulceration is Attenuated by Aspirin-Phosphatidylcholine: A Randomized Clinical Trial. Am J Gastroenterol 2011; 106(2):272-7